bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.

TitlebPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuse.
Publication TypeJournal Article
X
Enter your linkblue username.
Enter your linkblue password.
Secure Login

This login is SSL protected

Loading